Beyond such ambient trigger factors, our data raise the possibility that subclinical mutations in mitochondrial factors or in the IFNG/TLR3-pathway may contribute to the need of mysterin activation and may enhance the risk for MMD, acting as modifier genes. This evidence concerns the gene TLR3 and multiminicore myopathy.